国際医薬品開発研究ジャーナル

  • ISSN: 0975-9344
  • ジャーナル h-index: 44
  • 雑誌引用スコア: 59.93
  • ジャーナルのインパクトファクター: 48.80
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • シマゴ
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • OCLC-WorldCat
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ユーロパブ
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
  • リサーチゲート
このページをシェアする

抽象的な

Collaboration and Partnerships in Drug Discovery: Advancing Healthcare Together

Sumeet Singh*

Collaboration and partnerships have become increasingly important in drug discovery as the complexity of diseases and the costs associated with drug development continue to rise. This abstract will discuss the role of collaboration and partnerships in advancing healthcare through drug discovery. The paper will explore different types of collaborations, such as public-private partnerships, academic-industry partnerships, and inter-industry partnerships, and highlight their advantages and challenges. The benefits of collaboration in drug discovery, including access to complementary expertise, resources, and technology, will be discussed. Additionally, the importance of open innovation, precompetitive collaborations, and data sharing in accelerating drug discovery and reducing costs will be emphasized. Finally, the paper will examine successful collaborations and partnerships in drug discovery, providing case studies to illustrate how effective collaborations can lead to new treatments and therapies that improve patient outcomes. Overall, the paper will show how collaboration and partnerships are critical to advancing healthcare and drug discovery and highlight the need for continued collaboration in the field.

Keywords

Healthcare; Drug resistance; Collaboration; Research and development; Pharmaceutical industry; Drug discovery

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません